A bispecific antibody against IL-1β and IL-17A is beneficial for experimental rheumatoid arthritis

Feldmann, 2001, Anti-TNFα therapy of rheumatoid arthritis: what have we learned?, Annu Rev Immunol, 19, 163, 10.1146/annurev.immunol.19.1.163 Jeong, 2004, Effects of IL-1beta on gene expression in human rheumatoid synovial fibroblasts, Biochem Biophys Res Commun, 324, 3, 10.1016/j.bbrc.2004.09.011 Lipsky, 2000, Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in heumatoid arthritis with concomitant therapy study group, N Engl J Med, 343, 1594, 10.1056/NEJM200011303432202 Cohen, 2002, Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebocontrolled trial, Arthritis Rheum, 46, 614, 10.1002/art.10141 Bush, 2002, Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein, Arthritis Rheum, 46, 802, 10.1002/art.10173 Cheng, 2011, Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis, Autoimmunity, 44, 243, 10.3109/08916934.2010.517815 Fossiez, 1996, T-cell IL-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines, J Exp Med, 183, 2593, 10.1084/jem.183.6.2593 Jovanovic, 1998, IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1β and TNF-α, by human macrophages, J Immunol, 160, 3513, 10.4049/jimmunol.160.7.3513 Kasama, 2005, Neutrophil-derived cytokines: potential therapeutic targets in inflammation, Curr Drug Targets Inflamm Allergy, 4, 273, 10.2174/1568010054022114 Mitani, 2001, Polymorphonuclear leukocyte adhesion to articular cartilage is inhibited by cartilage surface macromolecules, Rheumatol Int, 20, 180, 10.1007/s002960000098 Brennan, 2008, Evidence that cytokines play a role in rheumatoid arthritis, J Clin Invest, 118, 3537, 10.1172/JCI36389 Issekutz, 1994, The role of tumour necrosis factor-alpha and IL-1 in polymorphonuclear leucocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis, Clin Exp Immunol, 97, 26, 10.1111/j.1365-2249.1994.tb06574.x Borghaei, 1998, Interleukin-4 suppression of interleukin-1-nducied transcription of collagenase (MMP-1) and stromelysin 1 (MMP-3) in human sy novial fibroblasts, Arthritis Rheum, 41, 1398, 10.1002/1529-0131(199808)41:8<1398::AID-ART8>3.0.CO;2-B Meller, 2000, Regulation of collagenase, stromelysin, and gelatinase B in human conjunctival and conjunctivochalasis fibroblasts by interleukin-1beta and tumor necrosis factor-alpha, Invest Ophthalmol Vis Sci, 41, 2922 Hur, 2006, Adenoviral delivery of IL-1 receptor antagonist abrogates disease activity during the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice, Immunol Lett, 106, 154, 10.1016/j.imlet.2006.05.006 Dinarello, 2004, Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation, Curr Opin Pharmacol, 4, 378, 10.1016/j.coph.2004.03.010 Furst, 2004, Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis, Clin Ther, 26, 1960, 10.1016/j.clinthera.2004.12.019 Fleischmann, 2003, Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial, Arthritis Rheum, 48, 927, 10.1002/art.10870 Schiff, 2000, Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis, Ann Rheum Dis, 59, i103, 10.1136/ard.59.suppl_1.i103 Jeong, 2004, Electrotransfer of human IL-1Ra into skeletal muscles reduces the incidence of murine collagen-induced arthritis, J Gene Med, 6, 1125, 10.1002/jgm.599 Chang, 2004, Dual biological functions of an interleukin-1 receptor antagonist-interleukin-10 fusion protein and its suppressive effects on joint inflammation, Immunology, 112, 643, 10.1111/j.1365-2567.2004.01910.x Kim, 2003, Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist, Gene Ther, 10, 1543, 10.1038/sj.gt.3302042 Inoue, 2003, Efficacy of daily compared to intermittent administration of IL-1Ra for protection against bone and cartilage destruction in collagen-challenged mice, Clin Exp Rheumatol, 21, 33 Zwerina, 2005, Pathogenesis of rheumatoid arthritis: targeting cytokines, Ann NY Acad Sci, 1051, 716, 10.1196/annals.1361.116 Zuurmond, 2011, Integration of efficacy, pharmacokinetic and safety assessment of interleukin-1 receptor antagonist in a preclinical model of arthritis, Regul Toxicol Pharmacol, 59, 461, 10.1016/j.yrtph.2011.01.014 Choy, 2001, Cytokine pathways and joint inflammation in rheumatoid arthritis, N Engl J Med, 344, 907, 10.1056/NEJM200103223441207 Suzuki, 2000, The role of p38 mitogen-activated protein kinase in IL-6 and IL-8 production from the TNF-alpha- or IL-1beta-stimulated rheumatoid synovial fibroblasts, FEBS Lett, 465, 23, 10.1016/S0014-5793(99)01717-2 Catrina, 2002, Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis, Rheumatology (Oxford), 41, 484, 10.1093/rheumatology/41.5.484 Goldring, 2002, Bone and joint destruction in rheumatoid arthritis: what is really happening?, J Rheumatol Suppl, 65, 44 Prowse, 1989, Interleukin-1 and interleukin-6 stimulate acute-phase protein production in primary mouse hepatocytes, J Leukoc Biol, 45, 55, 10.1002/jlb.45.1.55 Ishihara, 2002, IL-6 in autoimmune disease and chronic inflammatory proliferative disease, Cytokine Growth Factor Rev, 13, 357, 10.1016/S1359-6101(02)00027-8 Kishimoto, 2006, Interleukin-6: discovery of a pleiotropic cytokine, Arthritis Res Ther, 8, S2, 10.1186/ar1916 Gabay, 2006, Interleukin-6 and chronic inflammation, Arthritis Res Ther, 8, S3, 10.1186/ar1917 Houssiau Frédéric, 1988, Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides, Arthritis Rheum, 31, 784, 10.1002/art.1780310614 Nishimoto, 2004, Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial, Arthritis Rheum, 50, 1761, 10.1002/art.20303 Maini, 2006, Randomised clinical trial of the IL-6 receptor antagonist, tocilizumab (MRA), in rheumatoid arthritis patients with an incomplete response to methotrexate in Europe (CHARISMA), Arthritis Rheum, 54, 2817, 10.1002/art.22033 Maini, 2006, Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate, Arthritis Rheum, 54, 2817, 10.1002/art.22033 Smolen, 2008, Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial, Lancet, 371, 987, 10.1016/S0140-6736(08)60453-5 Jazayeri, 2010, Interleukin-6 subfamily cytokines and rheumatoid arthritis: role of antagonists, Int Immunopharmacol, 10, 1, 10.1016/j.intimp.2009.09.019 Cunha, 2010, IL-17 mediates articular hypernociception in antigen-induced arthritis in mice, Pain, 148, 247, 10.1016/j.pain.2009.11.006 Ruddy, 2004, Interleukin-17 regulates expression of the CXC chemokine LIX/CXCL5 in osteoblasts: implications for inflammation and neutrophil recruitment, J Leukoc Biol, 76, 135, 10.1189/jlb.0204065 Ruddy, 2004, Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members, J Biol Chem, 279, 2559, 10.1074/jbc.M308809200 Witowski, 2004, Interleukin-17: a mediator of inflammatory responses, Cell Mol Life Sci, 61, 567, 10.1007/s00018-003-3228-z Koenders, 2008, Interleukin-1 drives pathogenic Th17 cells during spontaneous arthritis in interleukin-1 receptor antagonist-deficient mice, Arthritis Rheum, 58, 3461, 10.1002/art.23957 Lubberts, 2003, IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance, J Immunol, 170, 2655, 10.4049/jimmunol.170.5.2655 Lubberts, 2004, Treatment with a neutralizing anti-murine interleukin-17 antibo dy after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion, Arthritis Rheum, 50, 650, 10.1002/art.20001 Zwerina, 2012, Anti IL-17A therapy inhibits bone loss in TNF-α-mediated murine arthritis by modulation of the T-cell balance, Eur J Immunol, 42, 413, 10.1002/eji.201141871 Kotake, 1999, IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis, J Clin Invest, 103, 1345, 10.1172/JCI5703 Chabaud, 2001, The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model, Arthritis Rheum, 44, 1293, 10.1002/1529-0131(200106)44:6<1293::AID-ART221>3.0.CO;2-T Feige, 2000, Anti-interleukin-1 and anti-tumor necrosis factor-alpha synergistically inhibit adjuvant arthritis in Lewis rats, Cell Mol Life Sci, 57, 1457, 10.1007/PL00000629 Bendele, 2000, Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis, Arthritis Rheum, 43, 2648, 10.1002/1529-0131(200012)43:12<2648::AID-ANR4>3.0.CO;2-M Schwab, 1993, Superantigen can reactivate bacterial cell wall-induced arthritis, J Immunol, 150, 4151, 10.4049/jimmunol.150.9.4151 Zwerina, 2004, Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction, Arthritis Rheum, 50, 277, 10.1002/art.11487 Plater-Zyberk, 2009, Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse model, Ann Rheum Dis, 68, 721, 10.1136/ard.2007.085431 Chabaud, 1998, IL-17 enhances the effects of IL-1 on IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes, J Immunol, 161, 409, 10.4049/jimmunol.161.1.409 Chen, 2011, IL-17RA aptamer-mediated repression of IL-6 inhibits synovium inflammation in a murine model of osteoarthritis, Osteoarthritis Cartilage, 19, 711, 10.1016/j.joca.2011.01.018 Cheung, 2008, Molecular mechanisms of cytokine and chemokine release from eosinophils activated by IL-17A, IL-17F, and IL-23: implication for Th17 lymphocytesme diated allergic inflammation, J Immunol, 180, 5625, 10.4049/jimmunol.180.8.5625 Myers, 1997, Collagen induced arthritis, an animal model of autoimmunity, Life Sci, 61, 1861, 10.1016/S0024-3205(97)00480-3 Durie, 1994, Collagen-induced arthritis as a model of rheumatoid arthritis, Clin Immunol Immunopathol, 73, 11, 10.1006/clin.1994.1164 Svensson, 1998, B cell-deficient mice do not develop type II collagen-induced arthritis (CIA), Clin Exp Immunol, 111, 521, 10.1046/j.1365-2249.1998.00529.x Terato, 1992, Induction of arthritis with monoclonal antibodies to collagen, J Immunol, 148, 2103, 10.4049/jimmunol.148.7.2103